Bristol-Myers Squibb Co (MIL:1BMY) EBIT: €9,802 Mil (TTM As of Mar. 2026)


MIL:1BMY Bristol-Myers Squibb Co MIL:1BMY
49 GF Score
Price €50.56
GF Value €48.51
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Bristol-Myers Squibb Co EBIT?

Bristol-Myers Squibb Co MIL:1BMY +3.14% 49 EBIT is €9,802 Mil as of Mar. 2026. GuruFocus rates MIL:1BMY with a GF Score™ of 49/100 and a GF Value™ of €48.51 (Fairly Valued). The stock has 7 warning signs investors should review.

Bristol-Myers Squibb Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €3,158 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €9,802 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Bristol-Myers Squibb Co's annualized ROC % for the quarter that ended in Mar. 2026 was 15.02%. Bristol-Myers Squibb Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 160.52%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Bristol-Myers Squibb Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 7.26%.


Bristol-Myers Squibb Co  (MIL:1BMY) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Bristol-Myers Squibb Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=11642.9 * ( 1 - 17.31% )/( (66393.376 + 61838.85)/ 2 )
=9627.51401/64116.113
=15.02 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=76892.452 - 5398.134 - ( 9114.742 - max(0, 19998.118 - 25099.06+9114.742))
=66393.376

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=74801.74 - 5999.64 - ( 9070.39 - max(0, 16571.67 - 23534.92+9070.39))
=61838.85

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Bristol-Myers Squibb Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=12632.46/( ( (7792.75 + max(-6123.18, 0)) + (7946.755 + max(-3517.09, 0)) )/ 2 )
=12632.46/( ( 7792.75 + 7946.755 )/ 2 )
=12632.46/7869.7525
=160.52 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(8191.568 + 2297.26 + 1282.708) - (5398.134 + 0 + 12496.582)
=-6123.18

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6874.155 + 2383.94 + 1628.795) - (5999.64 + 0 + 8404.34)
=-3517.09

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Bristol-Myers Squibb Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=9802.197/135052.069
=7.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bristol-Myers Squibb Co EBIT Related Terms


Bristol-Myers Squibb Co EBIT Historical Data

* Premium members only.

The historical data trend for Bristol-Myers Squibb Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bristol-Myers Squibb Co EBIT Chart

Bristol-Myers Squibb Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8,347.32 8,444.08 8,808.70 -6,142.56 9,581.03

Bristol-Myers Squibb Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,205.13 1,957.69 3,062.09 1,624.31 3,158.12

MIL:1BMY vs PFE, GILD, AMGN: EBIT Comparison

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bristol-Myers Squibb Co EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's EV-to-EBIT falls into.


MIL:1BMY
49GF Score
Bristol-Myers Squibb Co MIL:1BMY
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bristol-Myers Squibb Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €9,802 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €9,802 Mil mean?
Bristol-Myers Squibb Co (MIL:1BMY) has a EBIT of €9,802 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Bristol-Myers Squibb Co.
Is Bristol-Myers Squibb Co's EBIT too high?
Bristol-Myers Squibb Co's current EBIT is €9,802 Mil. Overall, Bristol-Myers Squibb Co has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's EBIT compare to PFE and GILD?
Bristol-Myers Squibb Co's EBIT of €9,802 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Bristol-Myers Squibb Co. Bristol-Myers Squibb Co's current EBIT is €9,802 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (MIL:1BMY) is currently considered Fairly Valued. The stock's GF Value™ is €48.51, compared to a current price of €50.56 — trading 4.2% above its estimated fair value. The current EBIT is €9,802 Mil. Bristol-Myers Squibb Co's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Bristol-Myers Squibb Co (MIL:1BMY), the current EBIT is €9,802 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bristol-Myers Squibb Co (MIL:1BMY) Overvalued in 2026?

Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued. The current stock price of €50.56 is trading 4.2% above its estimated GF Value™ of €48.51. GuruFocus considers Bristol-Myers Squibb Co to be Fairly Valued.

Key valuation signals for MIL:1BMY:

  • EBIT: €9,802 Mil
  • GF Value™: €48.51 vs. price of €50.56 (4.2% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the MIL:1BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bristol-Myers Squibb Co Business Description

Address Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
49GF Score

Get the complete analysis for MIL:1BMY

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€50.56
Price
€48.51
GF Value